Psychedelics-Assisted Therapies

Psychedelic healthcare insurance plans provider Enthea announced it will launch its services into 40 markets across the US in 2023 with the idea of making psychedelic-assisted therapies affordable, accessible and equitable through workplace benefits.  To aid in the rollout and help its...

Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule. It will be used in the upcoming Phase 1 clinical trial assessing the treatment of Alcohol Use Disorder (AUD). "Like other addictions,...